We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
-$396M
Cap. Flow %
-22.17%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 10.45%
2 Energy 0.15%
3 Communication Services 0%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACGN
226
DELISTED
Aceragen Inc
ACGN
$61K ﹤0.01%
+110
New +$75.3K
ALBO
227
PUT
DELISTED
Albireo Pharma Inc
ALBO
$50K ﹤0.01%
+6
New +$546
ATHE
228
Alterity Therapeutics
ATHE
$82.7M
$48K ﹤0.01%
+288
New +$159K
EYPT icon
229
CALL
EyePoint Inc
EYPT
$1B
$41K ﹤0.01%
+10
New +$440
AMRN
230
CALL
Amarin Corp
AMRN
$293M
$36K ﹤0.01%
10
-139
-93% -$5.17K
SEEL
231
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
CVM icon
232
CEL-SCI Corp
CVM
$21M
$20K ﹤0.01%
17
-2,200
-99% -$1.9M
ABUS icon
233
Arbutus Biopharma
ABUS
$871M
– –
-519,200
Closed -$9.33M
ACHV icon
234
Achieve Life Sciences
ACHV
$634M
– –
-160
Closed -$3.93M
ACHV icon
235
PUT
Achieve Life Sciences
ACHV
$634M
– –
0
– -$105K
AMRN
236
PUT
Amarin Corp
AMRN
$293M
– –
-10
Closed -$38K
ANIP icon
237
ANI Pharmaceuticals
ANIP
$1.84B
– –
-1,219
Closed -$24K
ARCT icon
238
Arcturus Therapeutics
ARCT
$163M
– –
-18,090
Closed -$2.28M
ASMB icon
239
PUT
Assembly Biosciences
ASMB
$507M
– –
-3
Closed -$61K
BAX icon
240
CALL
Baxter International
BAX
$12.6B
– –
-3,973
Closed -$15M
BCRX icon
241
CALL
BioCryst Pharmaceuticals
BCRX
$2.48B
– –
-1,576
Closed -$1.2M
BCRX icon
242
PUT
BioCryst Pharmaceuticals
BCRX
$2.48B
– –
-792
Closed -$602K
CLDX icon
243
CALL
Celldex Therapeutics
CLDX
$2.79B
– –
-225
Closed -$8.19M
CLDX icon
244
PUT
Celldex Therapeutics
CLDX
$2.79B
– –
-46
Closed -$1.67M
DVAX
245
DELISTED
Dynavax Technologies
DVAX
– –
-50,000
Closed -$980K
ENTA icon
246
Enanta Pharmaceuticals
ENTA
$367M
– –
-85,946
Closed -$3.12M
EW icon
247
CALL
Edwards Lifesciences
EW
$48.2B
– –
-10,188
Closed -$11.2M
EXAS
248
CALL
DELISTED
Exact Sciences
EXAS
– –
-1,025
Closed -$1.2M
GERN icon
249
Geron
GERN
$930M
– –
-29,638
Closed -$133K
GEVO icon
250
Gevo
GEVO
$363M
– –
-77
Closed -$663K
8 9
10
11 12

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.

Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.